Oxaliplatin
pharmaceutical drug
Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by infusion into a vein.
Common side effects include numbness, feeling tired, nausea, diarrhea, and low blood cell counts. Other serious side effects include allergic reactions. Use in pregnancy is known to harm the baby. Oxaliplatin is in the platinum-based antineoplastic family of medications. It is believed to work by blocking the duplication of DNA.
Oxaliplatin was patented in 1976 in Japan and approved for medical use in 1996 in Europe. It is on the 2023 World Health Organization's List of Essential Medicines.
Medical uses
Oxaliplatin is used for treatment of colorectal cancer, typically along with folinic acid (leucovorin) and fluorouracil in a combination known as FOLFOX or along with capecitabine in a combination known as CAPOX or XELOX. It also has uses in pancreatic cancer and stomach cancer or esophageal cancer. It may also be effective against breast cancer, germ cell tumor, ovarian cancer and non-small-cell lung cancer.
The public source identifies “Oxaliplatin” as pharmaceutical drug. This brief keeps that definition visible, then builds a research path around Oxaliplatin, pharmaceutical and drug.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Oxaliplatin”, the useful work is to connect “pharmaceutical drug” to the records capable of establishing context and consequence.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 15, 2025. The linked authority identifier is Q422327. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1976, 1996 and 2023.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Oxaliplatin”, its source revision and the description used here.
- Expand the search: follow Oxaliplatin primary sources, Oxaliplatin archive and Oxaliplatin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Oxaliplatin”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Oxaliplatin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.